Cargando…

Effect of FibroScan test in antiviral therapy for HBV-infected patients with ALT <2 upper limit of normal

OBJECTIVE: The objective of this study is to detect the liver stiffness of hepatitis B virus (HBV)-infected patients with an alanine aminotransferase (ALT) level of <2 upper limit of normal (2ULN) by FibroScan and compare histological changes to assess the progression of liver lesions and its tes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Xian-Zhi, Zhang, Shu-Feng, Yi, Jia-Yin, Wang, Bin, Sun, Hui-Qing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	De Gruyter 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7874573/ https://www.ncbi.nlm.nih.gov/pubmed/33817230 http://dx.doi.org/10.1515/biol-2020-0044

Ejemplares similares

Predictive value of FibroScan in detecting liver fibrosis in HBeAg negative patients with chronic hepatitis B whose HBV DNA 2000–20000 IU/ml with ALT 1–2 times the upper limit of normal and those with HBV DNA >20000 IU/ml and normal ALT
por: Danis, Nilay, et al.
Publicado: (2021)

Diagnostic Accuracy of FibroScan and Factors Affecting Measurements
por: Oeda, Satoshi, et al.
Publicado: (2020)

Liver Biopsy and FibroScan to Detect Early Histopathological Changes in Chronic HBV Patients Not Candidate for Treatment
por: Maklad, Sahar, et al.
Publicado: (2014)

The discriminatory ability of FibroScan liver stiffness measurement, controlled attenuation parameter, and FibroScan–aspartate aminotransferase to predict severity of liver disease in children
por: Chaidez, Alexander, et al.
Publicado: (2022)

Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis
por: Friedrich-Rust, Mireen, et al.
Publicado: (2010)

FibroScan Predicts Liver Fibrosis Progression in Chronic HBV Infection Patients with No Clear Indication for Antiviral Therapy: A Retrospective Cohort Study
por: Xu, Wei, et al.
Publicado: (2023)

Prospective Comparison of Transient Elastography Using Two Different Devices: Performance of FibroScan and FibroTouch
por: Serra, Joao Tiago, et al.
Publicado: (2020)

Safety Profile of Liver FibroScan in Patients with Cardiac Pacemakers or Implantable Cardioverter-Defibrillators
por: Chan, Yin, et al.
Publicado: (2017)

The clinical utility of FibroScan(®) as a noninvasive diagnostic test for liver disease
por: Wilder, Julius, et al.
Publicado: (2014)

Points to Be Considered When Applying FibroScan S Probe in Children With Biliary Atresia
por: Kim, Seung, et al.
Publicado: (2014)

A prospective comparative assessment of the accuracy of the FibroScan in evaluating liver steatosis
por: Jun, Baek Gyu, et al.
Publicado: (2017)

Liver Stiffness Measurement With FibroScan: Use the Right Probe in the Right Conditions!
por: Berger, Arthur, et al.
Publicado: (2019)

Estimation of Liver Fat by FibroScan in Patients With Nonalcoholic Fatty Liver Disease
por: Shrestha, Rupesh, et al.
Publicado: (2021)

The role of FibroScan in the era of metabolic (dysfunction)-associated fatty liver disease
por: Yilmaz, Yusuf, et al.
Publicado: (2023)

AST/ALT ratio, APRI, and FIB-4 compared to FibroScan for the assessment of liver fibrosis in patients with chronic hepatitis B in Bandar Abbas, Hormozgan, Iran
por: Moosavy, Seyed Hamid, et al.
Publicado: (2023)

FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran
por: Amernia, Behnaz, et al.
Publicado: (2021)

Correlates of hepatic stiffness by FibroScan(©) in a multicentric Italian cohort of HIV-infected patients
por: Tarquini, P, et al.
Publicado: (2010)

Use of aspartate aminotransferase to platelet ratio to reduce the need for FibroScan in the evaluation of liver fibrosis
por: Wong, Stephanie, et al.
Publicado: (2017)

FibroScan Detection of Fatty Liver/Liver Fibrosis in 2266 Cases of Chronic Hepatitis B
por: He, Tingshan, et al.
Publicado: (2020)

Direct comparison of the FibroScan XL and M probes for assessment of liver fibrosis in obese and nonobese patients
por: Durango, Esteban, et al.
Publicado: (2013)

Validation of Novel Fibrosis Index (NFI) for assessment of liver fibrosis: comparison with transient elastography (FibroScan)
por: Hussain, Azhar, et al.
Publicado: (2019)

The association of weight gain with nonalcoholic fatty liver disease and fibrosis detected by FibroScan in the United States
por: Wijarnpreecha, Karn, et al.
Publicado: (2022)

Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores
por: Sanyal, Arun J., et al.
Publicado: (2023)

Diagnostic accuracy of transient elastography (FibroScan) in detection of esophageal varices in patients with cirrhosis: A meta-analysis
por: Pu, Ke, et al.
Publicado: (2017)

Validation of Controlled Attenuation Parameter Measured by FibroScan as a Novel Surrogate Marker for the Evaluation of Metabolic Derangement
por: Huang, Zhimin, et al.
Publicado: (2022)

Clinical relevance of lipid panel and aminotransferases in the context of hepatic steatosis and fibrosis as measured by transient elastography (FibroScan®)
por: Chi-Cervera, Luis Alberto, et al.
Publicado: (2021)

Serum uric acid to creatinine ratio is associated with higher prevalence of NAFLD detected by FibroScan in the United States
por: Wang, Rusha, et al.
Publicado: (2022)

Utility of FibroScan-based scoring systems to narrow the risk group of nonalcoholic fatty liver disease with comorbidities
por: Miura, Kouichi, et al.
Publicado: (2022)

Feasibility study and reference values of FibroScan 502 with M probe in healthy preschool children aged 5 years
por: Zeng, Jing, et al.
Publicado: (2019)

Accuracy of FibroScan in analysis of liver fibrosis in patients with concomitant chronic Hepatitis B and nonalcoholic fatty liver disease
por: Li, Qiang, et al.
Publicado: (2020)

Performance of liver stiffness measurements obtained with FibroScan is affected by glucose metabolism in patients with nonalcoholic fatty liver disease
por: Yang, Xinyu, et al.
Publicado: (2021)

Comparing the controlled attenuation parameter using FibroScan and attenuation imaging with ultrasound as a novel measurement for liver steatosis
por: Hsu, Po-Ke, et al.
Publicado: (2021)

The FibroScan-aspartate aminotransferase score can stratify the disease severity in a Japanese cohort with fatty liver diseases
por: Fujii, Hideki, et al.
Publicado: (2021)

Correlation between Cumulative Methotrexate Dose, Metabolic Syndrome and Hepatic Fibrosis Detected by FibroScan in Rheumatoid Arthritis Patients
por: Lertnawapan, Ratchaya, et al.
Publicado: (2023)

FIB-4 is closer to FibroScan screen results to detecting advanced liver fibrosis and maybe facilitates NAFLD warning
por: Ding, Yuping, et al.
Publicado: (2023)

Effect of liver inflammation on accuracy of FibroScan device in assessing liver fibrosis stage in patients with chronic hepatitis B virus infection
por: Huang, Ling-Ling, et al.
Publicado: (2021)

2209. Discordance Between FibroSure and FibroScan Results in Hepatitis C and Human Immunodeficiency Virus Co-infected Patients Prior to Treatment for Hepatitis C Virus Infection
por: Tiyouh, Melissa, et al.
Publicado: (2018)

Discordance between Liver Biopsy and FibroScan® in Assessing Liver Fibrosis in Chronic Hepatitis B: Risk Factors and Influence of Necroinflammation
por: Kim, Seung Up, et al.
Publicado: (2012)

Effect of 48‐week pemafibrate on non‐alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan‐aspartate aminotransferase score
por: Hatanaka, Takeshi, et al.
Publicado: (2021)

FibroScan-AST Score Predicts 30-Day Mortality or Need for Mechanical Ventilation among Patients Hospitalized with COVID-19
por: Zelenika, Marko, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6gj8bu8k1s061124t07njb1o0j